Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of course they got paid. You don't create a revolutionary product for someone and not get paid. They are an engineering company and Oncosec is not.
REV-1 Quote from their clients list on their website seems very confident in what Oncosec has in store for the future of cancer therapy in deep tissue indications:
Established in 2011, OncoSec Medical Inc. is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. OncoSec approached REV·1 Engineering with a need for a new Electroporation & Genetic Payload Delivery device to reach internal cancerous tumors that could not be reached with their skin-based device.
REV·1 developed multiple design solutions addressing how to access the tumors, stabilize them, and deliver OncoSec's proprietary Genetic Payload, followed by electroporating the tumors.
REV·1 designed a simple hand-held unit that can be introduced in a minimally invasive out-patient setting to access tumors deep in the body. Currently in pre-clinical trials, this device, combined with OncoSec's proprietary gene therapy, will radically change the treatment of these deep-in-the-body, life-threatening tumors.
Time will tell if Oncosec has the juice or not.....but I think they do and so does REV-1.
Oncosec's trial with Merck is a (combination therapy with Keytruda) to treat the non-responders to Keytruda monotherapy in melanoma. I would suggest you go to Oncosec.com where you can read all the full details of how the electroporation with IL-12 (Immunopulse platform) works. It is truly amazing groundbreaking science that will most likely be expanded into solid tumors. So imagine that Merck can only treat 30% of cancer patients in most cancer types with Keytruda monotherapy. If Oncosec's Immunopulse platform proves successful in priming the immune system in combination therapy with Keytruda then that would be a huge deal. Seems very likely that if the interim results out Nov. 11th are good then Merck will be open to more collaboration with Oncosec in other cancer types beside melanoma.
Oncosec's next generation go-anywhere electroporation device could add alot of expansion capability to Merck's pipeline of treatments if they wanted to attack non-responders to keytruda monotherapy in several different indications such as (TNBC, Head and Neck cancer, bladder cancer). After all, the market for all those patients that don't respond to Keytruda monotherapy represents a huge untapped market. If Oncosec is the only company to date that is specifically targeting the non-responders to Keytruda then they are ahead of the game assuming the upcoming results are great.
I was watching the Symposium videos posted on Oncosec's homepage yesterday and still feel reassured that these top scientists with all their optimism 2 1/2 years ago are still right about the great potential that Oncosec has to offer with the Immunopulse Platform.
I totally agree with you. Any response rate above 30% for patients that have no alternative would be fabulous.
I think 50% would be a fair assumption. One other thing about the 64%-75% previous data. That data is from the long-term melanoma phase II study with a subset of patients that went on to receive Keytruda. According to Oncosec IR department those patients were not screened with the biomarker assay, which means they may or may not have been non-responders to keytruda monotherapy. So we will only know for sure if we are seeing above average response rates when data is released on Nov. 12th. I think 50% would be a good solid guess though based on previous data and that would be significant indeed.
Yes, and on the news the stock poped to over $3.50 on massive volume, highest in the company's history.
30% is a good number but I think Punit is intentionally setting the bar lower so we can over-deliver when results are released. Earlier this year at AACR we came out with 64% to 75% positive results. Looking good from here.
LOL.....Yeah, and pretty soon it will get even more exciting when this is trading at $4 a share.
LOL....Yikes!.....Stock going Up now!
LOL.....NIce. Stock goin' UP now!
LOL.....Wow, stock going Up!
LOL...stock going up.
Fast Track trial design may get Oncosec to market much faster. Other parties that may be interested in what Oncosec has may just force Merck to make an early move here if data next month is extra good. You never know what can happen overnight in the land of Biotech investing.
LOL....you first.
I don't believe Punit's Mission is solely to make himself a bundle of money. I think his mission is to bring a breakthrough cancer treatment to market to address the 70% of melanoma patients that will not respond to Keytruda monotherapy. If you believe otherwise state your proof. Is he under investigation by the SEC for fraud. I don't think so. Biotech is risky, so if anybody doesn't have the stomach for it they should not invest in it.
You are quite welcome for the advice. Good luck with your investment in Oncosec. Go Oncosec!.... and their mission to cure cancer and save many lives with their advancements in Immunotherapy... which is clearly the way cancer treatment is headed in the future.
LAGUNA BIOTECH CEO FORUM-October 16-18, 2016 Laguna Beach, CA
Some top notch CEO's at this Event. Wondering what we might have going on here.
Next up is:
BIO Investor Forum
October 18-19, 2016
San Francisco, CA
Sofinnova Japan Conference
October 25, 2016
Tokyo, Japan
Even better at 10+ billion dollars. I think I would have a heart attack if Oncosec was bought out for that type of valuation in the near term. Longer term I do believe it could reach that, and that is the type of investment I was hoping to get into 3 years ago when I started a position in Oncosec.
Titan, I noticed that Oncosec is listed in the GENE/CELL THERAPY category at the upcoming Bio Investor Forum. Maybe they will announce something about the multi-gene candidate at this forum?
I think what Oncosec has to offer is better than what Abbvie got for 5.8 Billion dollars for (Rova-T) in Stemcentrx deal. Big letdown after Asco data.
Analyst quote:
"Similar to chemotherapy, Rova-T appears to deliver responses that are transient and don’t translate into long-term survival benefits," wrote Cowen analyst Steve Scala in his note downgrading AbbVie stock to market perform from outperform.
Imagine the value of Oncosec at 5.8 Billion dollars. Not out of the question with the huge market they are targeting....and a lot of room for expansion beyond melanoma.
I think it is going to get a lot more exciting to be an Oncosec shareholder very soon. I would suggest not selling any shares even after data release next month if this pops. I am holding long-term.
Sharon Gargosky sounds very positive on the data they are seeing with the combo study which will be presented in November. Sounds like we are definitely headed for a registration trial soon.
Just trying to get the facts straight. The most important news of the day is that we now know when and where the combo interim data will be released. Let's hope we get some positive news on the conference call this afternoon too.
IR has responded to my e-mail about the events listed in the Media and Events Tab on their website. Apparently they are not presenting at every one of these events but they will now list the Events they are presenting at in the near term, so they have updated their website now to reflect this. So any conferences for November will be listed next month other than the event for data release PR'ed today.
Oncosec Events website tab updated now to reflect Presenting Events for October. The PR today is good news; now we know combo update data is definitely being released soon with no delays.
Upcoming Events for Oncosec: To gain some clarity on the conferences Oncosec will or will not be presenting at I just sent a message to IR. Seems like a lot of events are scheduled under the Media & Events tab on their website but in the most recent PR some events are missing from October which leads me to wonder if they are simply attending some of the events rather than presenting at them. I guess it is wishful thinking that they would be presenting at this many conferences in such a short timeframe, but we will see what they have to say about this. Guessing which events they might release pertinent data. Maybe on the conference call we get some clarity.
Titan, I agree they may PR some news from ESMO after hours or tomorrow. The caption on the events link on their website does say: The OncoSec Leadership Team Will Be Attending The Following Events
....so it would seem they are actually attending all the events listed.....which is freakin' awesome.
The next few months re going to be fun for sure.
Maybe we get a PR in the morning to shed some light on this. We could see a big lift to start the next week. Thumbs Up!
This is looking good! Lots of events means they are going to make a strong push to publicize upcoming data. My eyes nearly popped out when I saw all the upcoming events listed. Go Oncosec!
UPCOMING EVENTS POSTED IN EVENTS SECTION ON ONCOSEC WEBSITE FOR OCT, NOV, DEC:
I HOPE WE ARE PRESENTING AT ALL THESE EVENTS. ALOT GOING ON HERE IF WE ARE.
ESMO 2016 Congress
October 7-11, 2016 | Copenhagen, Denmark
Annual Meeting International Cytokine and Interferon Society (ICIS)
October 16-19, 2016 | San Francisco, CA
Laguna Biotech CEO Forum
October 16-18, 2016 | Laguna Beach, CA
BIO Investor Forum
October 18-19, 2016 | San Francisco, CA
Sofinnova Japan Conference
October 25, 2016 | Tokyo, Japan
World Cancer Congress
October 31 – November 3, 2016 | Paris, France
BIOSafe Meetings
November 2-3, 2016 | Basel, Switzerland
ESMO Immuno-Oncology
November 4-6, 2016 | Lausanne, Switzerland
Society for Melanoma Research (SMR)
November 6-9, 2016 | Boston, MA
Credit Suisse Healthcare Conference
November 7-9, 2016 | Phoenix, AZ
World Pharma Congress
November 7-9, 2016 | Las Vegas, NV
Society for Immunotherapy of Cancer (SITC)
November 9-13, 2016 | National Harbor, MD
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting
November 13-17, 2016 | Denver, CO
Annual NeoAntigen Summit
November 14-17, 2016 | Boston, MA
Stifel Nicolaus Weisel Healthcare Conference 2016
November 15-16, 2016 | New York City, NY
Inaugural Cancer Immunotherapy Summit
November 21-22, 2016 | Berlin, Germany
International Conference on Translational Medicine
November 28-30, 2016 | San Francisco, CA
International Conference on Translational Medicine
November 28-30, 2016 | San Francisco, CA
Piper Jaffray Annual Healthcare Conference
November 29-30, 2016 | New York City, NY
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
November 29 – December 2,2016 | Munich, Germany
International Conference and Exhibition on Immunology
December 1-2, 2016 | Chicago, IL
World Congress on Cancer Therapy
December 5-7,2016 | Philadelphia, PA
LD Micro Conference
December 6-8, 2016 | Los Angeles, CA
San Antonio Breast Cancer Symposium (SABCS)
December 6-10, 2016 | San Antonio, TX
A new kind of treatment is working better than chemotherapy in some lung cancer patients:
http://www.aol.com/article/2016/10/09/a-new-kind-of-treatment-is-working-better-than-chemotherapy-in-s/21577656/
Oncosec collaborator, Merck is making good headway this weekend with lung cancer data.
Immunotherapy is revolutionizing cancer-Oncosec article in The Crescent-News:
http://www.crescent-news.com/news/local_health/immunotherapy-is-revolutionizing-cancer/article_c9c83271-674e-5850-84b9-e2c8c7205e21.html
Merck presented data today with positive results for Keytruda besting Bristol Myers in Lung Cancer as first line therapy. Now how are they going to take their best-in-class Keytruda for lung cancer and treat the 70% of the population who are non-responsive to pd-1 therapy?......ONCOSEC combo therapy with Keytruda!
The Keytruda study results "may establish a new standard of care" for first-line treatment of lung cancer patients whose tumors have high levels of PD-L1, Bruce E. Johnson, a lung-cancer specialist at Dana-Farber Cancer Institute in Boston, wrote in a NEJM editorial accompanying the Keytruda results.
Maybe a combo of Keytruda and Immunopulse IL-12 would earn a first-line therapy indication for the 70% of the population who do not respond to pd-1 therapy alone and who would rather not be poisoned with chemo and radiation.
Post from Oncosec Facebook page about Triple Negative Breats Cancer:
With proper knowledge, support and tips, breast cancer patients can be well equipped and ready to win the fight against cancer. In honor of #BreastCancer Awareness Month, read this inspiring story from
@SusanGKomen about a triple-negative breast cancer survivor:
http://sgk.mn/2dAw6Sk
Absolutely Titan. Merck is a much more cautious company after the massacre that was Vioxx. Under the leadership of Ken Frazier, he has been navigating Merck into steadier waters with acquisitions, partnerships, and collaborations. Immunotherapy has a century long history that is only starting to take root. Merck is most likely waiting on the combo results just like us all before making any more commitment just yet. If the results are good and the share price starts to shoot up then Merck will pay more for a therapy that has a great chance to make it to market. I think the mindset might be like this: Why risk wasting 100-500 million dollars now before results or spend 1+ Billion dollars later for an approved therapy that can be expanded exponentially later with little risk. From the viewpoint of a CEO you have to be watching where those millions of dollars are going because you have many many institutional investors to answer to.
Absolutely their are many competent companies working on cancer therapies....and Oncosec is a competent company collaborating with Merck, one of the largest drug companies in the world (and that absolutely means something). Oncosec share price does not currently reflect that but I believe that it will in the future. GO ONCOSEC!
I would bet the term "collaborator" will change to "partner" in the future when a dollar amount is involved, unless we are presented with a buyout.
I'm going to take a wild guess and say that Merck 100% knows who Oncosec is or they would not have provided Keytruda to Oncosec for the use in a combination study with Immunopulse IL-12. Just a crazy hunch on my part. GO ONCOSEC!
Dr. Pierce seems to not be in need of a better better paying job according to his Linked In profile:
Opportunities Robert is looking for:
Joining a nonprofit board
Skills-based volunteering (pro bono consulting)
I would guess he knows a good stock option payoff is coming in the near future.
GO ONCOSEC!
You are quite welcome for the advice. Go Oncosec! Cancer patients are in dire need of new therapies to treat their life-threatening disease. Lets give a thumbs up to humanity and all those fighting for a good cause here.
Merck and Bristol Myers reporting positive results this weekend with Merck coming out ahead in Bladder Cancer (25% ORR vs. 19% for Bristol). Bladder cancer is another indication that Immunopulse could be pared with Keytruda. Merck could enhance their entire Keytuda franchise with the addition of immunopulse IL-12 for multiple indications.
Keep the faith here folks. My advice to all investors in Oncosec is to stretch your timeline out as much as needed and don't panic sell this. The market will eventually give Oncosec the respect they deserve.
With the deep pockets Merck has, they could start as many fast track combo studies they want for multiple cancer indications with immunopulse IL-12. Keytruda is the best pipeline drug they have and they will need to milk it for all they can. Money will only continue to spread out in search of they best indications......and I believe Oncosec will benefit once we get the combo results in the next few months.